Process for the preparation of purine derivatives

Information

  • Patent Grant
  • 6187922
  • Patent Number
    6,187,922
  • Date Filed
    Wednesday, January 27, 1999
    26 years ago
  • Date Issued
    Tuesday, February 13, 2001
    23 years ago
Abstract
The present invention provides for the compound and synthesis of 9-(4-acetoxy-3-acetoxymethylbutyl)-2-amino-6-chloropurine, which compound is an intermediate involved in the synthesis of penciclovir and famciclovir.
Description




The present invention relates to a process for the preparation of novel compounds, which are of potential use as antiviral agents, to a process for their reparation and to their use as pharmaceuticals.




U.S. Pat. Nos. 5,075,445 and 5,246,937, the subject matter of which is incorporated herein by reference, disclose antiviral compounds penciclovir (Example 4 of '445) and famciclovir (Example 2 of '937) and methods for their preparation. 2-Amino-6-chloropurine (ACP) is 9-substituted with an appropriate side chain precursor, followed by conversion of the 6-chloro moiety to a hydroxy moiety (i.e. to form a guanine) or hydrogen (a 2-aminopurine).




In particular, beginning column 4 of '445, and column 3 of '937, a process is described for the preparation of such purine derivatives wherein the hydroxy groups in the 9-(4-hydroxy-3-hydroxymethylbut-1-yl) substituent are in acylated form, i.e. the ACP is reacted with 2-acyloxymethyl-4-(leaving group)-but-1-yl acylate. The leaving group may be halo, such as chloro, bromo or iodo although alternative leaving groups, such as tosylate or methanesulphonate may be employed. The acyl groups have advantages over the alternative protecting groups already described in acyclonucleoside chemistry in providing a good yield of 9-substitution and avoiding by-products which are difficult to isolate.




The following examples illustrate the process of the invention to form 9-(4-acetoxy-3-acetoxymethylbut-1-yl)-2-amino-6-chloropurine, (DACP). The following descriptions illustrate the preparation of side chain intermediates. Penciclovir is prepared from DACP according to the method described in '445 column 14, lines 4-16 and famciclovir is prepared from DACP according to the method described in Example 2 of '937.











EXAMPLE 1




2-Acetoxymethyl-4-bromobutyl acetate was reacted with ACP as described in Examples 11 and 10 of '445.




EXAMPLE 2




A mixture of ACP (10.0 mmol), 2-acetoxymethyl-4-iodobutyl acetate (3.30 g, 10.5 mmol), and anhydrous potassium carbonate (2.07 g, 15.0 mmol) was stirred for 18 hours at ambient temperature in dry DMF (40 ml) under an atmosphere of dry nitrogen. The mixture was then filtered to remove insoluble material, which was washed well with DMF. The combined filtrates were evaporated under reduced pressure and the residue purified directly by column chromatography on silica gel (150 g), eluting with various dichloromethane-methanol mixtures. Fractions containing the first-eluting N-9 isomer, and the second-eluting N-7 isomer were separately combined, rigorously evaporated and weighed. The N-9:N-7 alkylated product ratio obtained from the isolated weights was checked by integration of the respective H-8


1


HNMR signals in the spectrum of the crude residue.




9-(4-Acetoxy-3-acetoxymethylbutyl)-2-amino-6-chloropurine and 7-(4-acetoxy-3-acetoxymethylbutyl)-2-amino-6-chloropurine




Column eluant dichloromethane-methanol 25:1.




9-isomer, 75%, m.p.


134-136° (ethyl acetate-diethyl ether).








1


HNMR: 1.80-2.05 (m 3H,CHCH


2


), 2.00 (s,6H,2×COCH


3


), 4.03 (d,4H,2×CH


2


O), 4.15 (t,2H,CH


2


N), 6.87 (brs,2H,NH


2


), 8.16 (s,1H,H-8).






13


CNMR: 20.47 (2×CH


3


), 27.75 (CH


2


), 34.45 (CH), 40.88 (CH


2


N), 63.43 (2×CH


2


O), 123.43 (C-5), 143.07 (C-8), 149.34 (C-6), 154.02 (C-4), 159.68 (C-2), 170.27 (2×CO).




U.V. λ


max


223.5 (ε27.600), 248.5 (5,800), 310 (7,700).




Found; C:47.14, H:4.97, N:19.69. C


14


H


18


N


5


O


4


Cl requires; C:47.26, H:5.10, N:19.68%.




7-isomer, 15%, m.p. 159-161° (dec). (butanol).






1


HNMR: 1.60-2.10 (m,3H,CHCH


2


), 2.00 (s,6H,2×COCH


3


), 4.00 (d,4H,2×CH


2


O), 4.34 (m,2H,CH


2


N), 6.56 (brs,2H,NH


2


), 8.33 (s,1H,H-8).






13


CNMR: 20.41 (2×CH


3


), 29.80 (CH


2


), 34.51 (CH), 44.06 (CH


2


N), 63.46 (2×CH


2


O), 114.65 (C-5), 141.97 (C-6), 149.28 (C-8), 159.81 (C-2), 164.24 (C-4), 170.12 (2×CO).




U.V. λ


max


222.5 (ε23.600), 253.5sh (3,700), 323 (5,400)




Found; C:47.31, H:5.17, N:19.88. C


14


H


18


N


5


O


4


Cl requires; C:47.26, H:5.10, N:19.68%.




2-Acetoxymethyl-4-bromobutyl acetate was Prepared as Described in Examples 5-8 of '445




2-Acetoxymethyl-4-iodobutyl acetate was prepared as follows:




a) To a stirred solution of 2-(2-benzyloxyethyl)propane-1,3-diol (J. Org. Chem., 1981, 46, 3204) (10.0 g, 47.6 mmol), 4-dimethylaminopyridine (0.55 g, 4.5 mmol), and pyridine (12.3 ml, 0.15 mol) in dichloromethane (54 ml) at −10° C. was added dropwise acetic anhydride (13.2 ml, 0.14 mol) over 20 minutes. After completion of the addition, the reaction mixture was stirred for a further 1 hour at 0° C., then diluted with dichloromethane (100 ml) and washed with 2M hydrochloric acid (2×50 ml), saturated sodium bicarbonate solution (50 ml), and brine (50 ml), dried (MgSO


4


), and evaporated to give 2-acetoxymethyl-4-benzyloxybutyl acetate as a light yellow oil 13.2 g, 94%). b.p. 160-165°/0.5mm.






1


HNMR: 1.62 (q,2H,CHCH


2


), 2.00 (s,6H,2×CH


3


), 2.15 (m,1H,CH), 3.51 (t,2H,CH


2


CH


2


O), 4.03 (m,4H,2×CH


2


O), 4.46 (s,2H,OCH


2


Ph), 7.33 (m,5H,Ph).






13


CNMR: 20.31 (2×CH


3


), 27.93 (CHCH


2


), 34.40 (CH), 63.73 (2×CH


2


O), 67.22 (CH


2


CH


2


O), 71.99 (CH


2


Ph), 127.22, 127.30, 128.09, 138.54 (Ph), 170.13 (2×CO).




Found; C:65.07, H:7.76. C


16


H


22


O


5


requires; C:65.29, H:7.53%.




b) A solution of 2-acetoxymethyl-4-benzyloxybutyl acetate (15.5 g, 52.7 mmol) in ethanol (200 ml) was hydrogenated for 18 hours at ambient temperature over 10% palladium-carbon (2 g). Filtration and evaporation afforded the corresponding alcohol (10.2 g) as a colourless oil.




c) To a stirred solution of the above oil and triethylamine (10.4 ml, 74.8 mmol) in dichloromethane (100 ml) cooled to −5° C. was added a solution of methanesulphonyl chloride (4.6 ml, 59.5 mmol) in dichloromethane (30 ml) dropwise over 30 minutes. After completion of the addition, the reaction mixture was stirred for a further 1 hour at −5° C., then washed with 2M hydrochloric acid (2×100 ml), saturated sodium bicarbonate solution (100 ml), and brine (100 ml), dried (MgSO


4


) and evaporated to afford the corresponding methanesulphonate (14.1 g) as a pale yellow oil.




d) A mixture of the above oil and sodium iodide (15.0 g, 0.1 mol) was stirred under reflux for 2 hours in acetone (150 ml), then cooled, poured into water (300 ml), and extracted with diethyl ether (3×150 ml). The combined ether extracts were washed with 10% sodium metabisulphite solution (250 ml), and brine (250 ml), dried (MgSO


4


) and evaporated to give a pale oil. This was purified by flash column chromatography on silica, eluant hexane-diethyl ether 3:2 affording the title compound as a colourless oil (13.1 g, 79% from 2-acetoxymethyl-4-benzyloxybutyl acetate).






1


HNMR: 1.88 (q,2H,CH


2


), 2.02 (s,6H,2×CH


3


), 2.10 (m,1H,CH), 3.33 (t,2H,CH


2


I), 4.02 (d,4H,2×CH


2


O).






13


CNMR: 5.01 (CH


2


I), 20.48 (2×CH


3


), 32.04 (CH


2


), 37.87 (CH), 62.86 (2×CH


2


O), 170.02 (2×CO).




EI-MS. m/e: 314 (M


+


), 254 (M


+


-HOAc), 211 (M


+


-HOAcAc), 187 (M


+


-I).




Found; C:34.56, H:4.99. C


9


H


15


O


4


I requires; C:34.42, H:4.81%.



Claims
  • 1. A process for the preparation of 9-(4-acetoxy-3-acetoxymethylbut-1-yl)-2-amino-6-chloropurine which process comprises the reaction of 2-amino-6-chloropurine with 2-acetoxymethyl-4-(leaving group)-but-1-yl acetate.
  • 2. The process according to claim 1 wherein the leaving group is halo.
  • 3. The process according to claim 2 wherein the leaving group is bromo.
  • 4. The process according to claim 2 wherein the leaving group is iodo.
Priority Claims (6)
Number Date Country Kind
8322199 Aug 1983 GB
8325271 Sep 1983 GB
8408322 Mar 1984 GB
8423833 Sep 1984 GB
8510331 Apr 1985 GB
8520618 Aug 1985 GB
Parent Case Info

This application is a divisional of CPA application U.S. Ser. No. 08/884,731, filed Jun. 30, 1997, now U.S. Pat. No. 5,886,215, which is a divisional of U.S. Ser. No. 08/258,167, filed Jun. 10, 1994, now U.S. Pat. No. 5,684,153, which application is a continuation in part application of two U.S. application Ser. Nos., U.S. Ser. No. 08/132,082, filed Oct. 5, 1993 (abandoned), and U.S. Ser. No. 07/918,111, filed Jul. 20, 1992 (abandoned); the application U.S. Ser. No. 08/132,082, filed Oct. 5, 1993 (abandoned), is a continuation of U.S. Ser. No. 07/825,440, filed Jan. 22, 1992, now U.S. Pat. No. 5,250,688, which is a continuation of U.S. Ser. No. 07/285,399, filed Dec. 15, 1988 (abandoned), which is a continuation of U.S. Ser. No. 07/777,188, filed Sep. 18, 1985 (abandoned); the application U.S. Ser. No. 07/918,111, (noted above), filed July 20, 1992 (abandoned) is a continuation of U.S. Ser. No. 07/607,403, filed Oct. 31, 1990 (abandoned) which is a continuation of U.S. Ser. No. 07/085,216, filed Aug. 12, 1987, now U.S. Pat. No. 5,075,455, which is a continuation of U.S. Ser. No. 07/641,300 filed Aug. 16, 1984 (abandoned).

US Referenced Citations (11)
Number Name Date Kind
4146715 Schaeffer Mar 1979
4451478 Simon et al. May 1984
4461757 Ogilivie Jul 1984
4495190 Hagberg et al. Jan 1985
4579849 MacCoss et al. Apr 1986
4609662 Krenitsky Sep 1986
4798833 Johansson et al. Jan 1989
4845084 Hannah et al. Jul 1989
5075445 Jarvest Dec 1991
5246937 Harnden et al. Sep 1993
5684153 Geen Nov 1997
Foreign Referenced Citations (16)
Number Date Country
0 055 23 Dec 1981 EP
0 055 239 Jun 1982 EP
0 141 927 May 1985 EP
0 152 316 Aug 1985 EP
0 186 640 Jul 1986 EP
352953 Jan 1990 EP
355986 Feb 1990 EP
369583 May 1990 EP
404296 Dec 1990 EP
1 523 865 Sep 1978 GB
2 104 070 Mar 1983 GB
2 122 197 Jan 1984 GB
2 122 198 Jan 1984 GB
2 130 204 May 1984 GB
2 151 622 Jul 1985 GB
WO 9323401 Nov 1993 WO
Non-Patent Literature Citations (17)
Entry
Geen et al., Tetrahedron, 46:19, 6903-6914, 1990.
Chu et al., J. Heterocylic Chem., 23, 289 (1986).
Robins et al., Can. J. Chem., 60 (1982).
Kjellberg et al., Nucleosides& Nucleotides, 8:2, 225-256 (1989).
Gillen, Synthesis and properties of Novel Nucleoside and Nucleotide Analogues, Ph.D. Thesis (Apr. 19, 1980).
Pandit et al., Synthetic Communication, 2(6) 345-351 (1972).
Keller et al., Biochem. Pharm. 30(22) 3071-3077 (1981).
Ericson et al., Antimicrobial Agents and Chemotherapy, 27(5), 753-759 (1985).
Ashton et al., J. Med. Chem., 28, 926-933 (1985).
Oberg et al., J. Antimicrob. Chemother., 14(Suppl A), 5-26 (1984).
Grose, PhD. Thesis, Synthesis of Nucleoside Analogues, Univ. of Amersterdam (1971).
Stewart et al., “The Peptides”, vol. 3, pp. 172, 180, 181 (1981).
Tippie, et al., Nucleosides & Nucleotide, 3(5), 525-535 (1984).
Smith et al., Antimicrob. Agents Chemotherapy, vol. 22, No. 1, p. 55-61 (Jul. 1982).
Martin et al., J. Med. Chem., vol. 22, pp. 759-761 (1983).
McGee et al., J. Med. Chem., vol. 28, pp. 1242-1245 (1985).
Harnden et al., J. Chem Soc. Perkin Trans., I, pp. 2207-2213 (1989).
Continuations (6)
Number Date Country
Parent 07/825440 Jan 1992 US
Child 08/132082 US
Parent 07/285399 Dec 1988 US
Child 07/825440 US
Parent 07/777188 Sep 1985 US
Child 07/285399 US
Parent 07/607403 Oct 1990 US
Child 07/918111 US
Parent 07/085216 Aug 1987 US
Child 07/607403 US
Parent 07/641300 Aug 1984 US
Child 07/085216 US
Continuation in Parts (2)
Number Date Country
Parent 08/132082 Oct 1993 US
Child 08/258167 US
Parent 07/918111 Jul 1992 US
Child 08/258167 US